keyword
MENU ▼
Read by QxMD icon Read
search

Intraductal pancreatic mucinous neoplasm

keyword
https://www.readbyqxmd.com/read/28802775/catastrophic-antiphospholipid-syndrome-caps-induced-ischemic-pancreatic-ducts-injury-mimicking-intraductal-papillary-mucinous-neoplasm-ipmn
#1
Léa Savey, Jean-Charles Piette, Jérome Bellanger, Laurent Palazzo, Zahir Amoura, Alain Sauvanet, Jean-François Pouget-Abadie, Philippe Sogni, Joseph Emmerich, Nathalie Costedoat-Chalumeau
OBJECTIVES: Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening disease characterized by multiple small-vessel occlusions of rapid onset. Ischemic pancreatic duct lesions secondary to CAPS have never been reported. METHODS: We describe 4 patients who presented lesions suspected to be intraductal papillary mucinous neoplasm (IPMN) of the pancreas following a CAPS. RESULTS: All patients had a history of CAPS months or years before the IPMN diagnosis...
July 10, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28801818/-branch-duct-intraductal-papillary-mucinous-neoplasm-surgical-approach
#2
REVIEW
J Kaiser, M W Büchler, T Hackert
Due to increasing precision of modern imaging modalities, intraductal papillary mucinous neoplasms (IPMN) of the pancreas are found with increasing prevalence. Despite their malignant potential IPMN are often kept under surveillance and are not immediately resected. The 2012 International Consensus Guidelines of Fukuoka have been widely accepted for the management of IPMN. They recommend surgical resection for branch duct IPMN with "high risk stigmata", while branch duct IPMN with "worrisome features" should undergo observation without immediate resection...
August 11, 2017: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/28776576/gnas-mutations-in-primary-mucinous-and-non-mucinous-lung-adenocarcinomas
#3
Lauren L Ritterhouse, Marina Vivero, Mari Mino-Kenudson, Lynette M Sholl, A John Iafrate, Valentina Nardi, Fei Dong
GNAS mutations have been described in mucinous and non-mucinous epithelial neoplasms of the appendix, pancreas, and colon, with hotspot GNAS mutations found in up to two-thirds of pancreatic intraductal papillary mucinous neoplasms. Additionally, many GNAS-mutated tumors have concurrent mutations in the Ras/Raf pathway. The clinicopathologic features of GNAS-mutated lung carcinomas, however, have not yet been characterized. Primary lung carcinomas from Brigham and Women's Hospital (n=1282) or Massachusetts General Hospital (n=1070) were genotyped on a targeted massively parallel sequencing panel of oncogenes and tumor suppressor genes including GNAS...
August 4, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28776573/pancreatic-intraductal-tubulopapillary-neoplasm-is-genetically-distinct-from-intraductal-papillary-mucinous-neoplasm-and-ductal-adenocarcinoma
#4
Olca Basturk, Michael F Berger, Hiroshi Yamaguchi, Volkan Adsay, Gokce Askan, Umesh K Bhanot, Ahmet Zehir, Fatima Carneiro, Seung-Mo Hong, Giuseppe Zamboni, Esra Dikoglu, Vaidehi Jobanputra, Kazimierz O Wrzeszczynski, Serdar Balci, Peter Allen, Naoki Ikari, Shoko Takeuchi, Hiroyuki Akagawa, Atsushi Kanno, Tooru Shimosegawa, Takanori Morikawa, Fuyuhiko Motoi, Michiaki Unno, Ryota Higuchi, Masakazu Yamamoto, Kyoko Shimizu, Toru Furukawa, David S Klimstra
Intraductal tubulopapillary neoplasm is a relatively recently described member of the pancreatic intraductal neoplasm family. The more common member of this family, intraductal papillary mucinous neoplasm, often carries genetic alterations typical of pancreatic infiltrating ductal adenocarcinoma (KRAS, TP53, and CDKN2A) but additionally has mutations in GNAS and RNF43 genes. However, the genetic characteristics of intraductal tubulopapillary neoplasm have not been well characterized. Twenty-two intraductal tubulopapillary neoplasms were analyzed by either targeted next-generation sequencing, which enabled the identification of sequence mutations, copy number alterations, and selected structural rearrangements involving all targeted (≥300) genes, or whole-exome sequencing...
August 4, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28770404/validation-of-the-american-gastroenterological-association-guidelines-on-management-of-intraductal-papillary-mucinous-neoplasms-more-than-5%C3%A2-years-of-follow-up
#5
Koh Imbe, Naoyoshi Nagata, Yuya Hisada, Yusuke Takasaki, Katsunori Sekine, Saori Mishima, Akihito Kawazoe, Tsuyoshi Tajima, Takuro Shimbo, Mikio Yanase, Junichi Akiyama, Kazuma Fujimoto, Naomi Uemura
OBJECTIVES: Recent guidelines suggest that imaging surveillance be conducted for 5 years for patients with at most one high-risk feature. If there were no significant changes, surveillance is stopped. We sought to validate this follow-up strategy. METHODS: In study 1, data were analysed for 392 patients with intraductal papillary mucinous neoplasms (IPMNs) and at most one high-risk feature who were periodically followed up for more than 1 year with imaging tests...
August 2, 2017: European Radiology
https://www.readbyqxmd.com/read/28762074/the-oral-microbiota-in-patients-with-pancreatic-cancer-patients-with-ipmns-and-controls-a-pilot-study
#6
Sara H Olson, Jaya Satagopan, Youming Xu, Lilan Ling, Siok Leong, Irene Orlow, Amethyst Saldia, Peter Li, Pamela Nunes, Vincent Madonia, Peter J Allen, Eileen O'Reilly, Eric Pamer, Robert C Kurtz
PURPOSE: Poor oral health appears to be a risk factor for pancreatic cancer, possibly implicating the oral microbiota. In this pilot study, we evaluated the characteristics of the oral microbiota in patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasms (IPMN), and healthy controls. METHODS: Forty newly diagnosed PDAC patients, 39 IPMN patients, and 58 controls, excluding current smokers and users of antibiotics, provided saliva samples...
July 31, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28739282/long-term-risk-of-pancreatic-malignancy-in-patients-with-branch-duct-intraductal-papillary-mucinous-neoplasm-in-a-referral-center
#7
Ilaria Pergolini, Klaus Sahora, Cristina R Ferrone, Vicente Morales-Oyarvide, Brian M Wolpin, Lorelei A Mucci, William R Brugge, Mari Mino-Kenudson, Manuel Patino, Dushyant V Sahani, Andrew L Warshaw, Keith D Lillemoe, Carlos Fernández-Del Castillo
BACKGROUND & AIMS: Little is known about development of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs). We evaluated long-term outcomes of a large cohort of patients with BD-IPMNs to determine risk of malignancy and define a subset of low-risk BD-IPMNs. METHODS: We performed a retrospective analysis of data from 577 patients with suspected or presumed BD-IPMN under surveillance at the Massachusetts General Hospital. Patients underwent cross-sectional imaging analysis at 3 months or later after their initial diagnosis...
July 21, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28739154/prostaglandin-e2-a-pancreatic-fluid-biomarker-of-intraductal-papillary-mucinous-neoplasm-dysplasia
#8
Michele T Yip-Schneider, Rosalie A Carr, Huangbing Wu, C Max Schmidt
BACKGROUND: With the increased frequency of diagnostic imaging, pancreatic cysts are now detected in >3% of American adults. Most of these are intraductal papillary mucinous neoplasm (IPMN) with well-established but variable malignant potential. A biomarker that predicts malignant potential or dysplastic grade would help determine which IPMN require removal or can be safely observed. We previously reported that pancreatic fluid prostaglandin E2 (PGE2) levels may have promise as a predictor of IPMN dysplasia and seek to validate these results in the current study...
July 21, 2017: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/28735806/revisions-of-international-consensus-fukuoka-guidelines-for-the-management-of-ipmn-of-the-pancreas
#9
REVIEW
Masao Tanaka, Carlos Fernández-Del Castillo, Terumi Kamisawa, Jin Young Jang, Philippe Levy, Takao Ohtsuka, Roberto Salvia, Yasuhiro Shimizu, Minoru Tada, Christopher L Wolfgang
The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In particular, the indications for resection of branch duct IPMN have changed from early resection to more deliberate observation as proposed by the international consensus guidelines of 2006 and 2012. Another guideline proposed by the American Gastroenterological Association in 2015 restricted indications for surgery more stringently and recommended physicians to stop surveillance if no significant change had occurred in a pancreatic cyst after five years of surveillance, or if a patient underwent resection and a non-malignant IPMN was found...
July 13, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/28725064/editorial-stopping-pancreatic-cyst-surveillance
#10
James J Farrell
The management of patients with pancreatic cysts, especially presumed branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), remains a challenge. BD-IPMNs carry a very low risk of malignancy and occur in predominantly older individuals who often die from causes not related to their pancreatic disease. The specific decision to stop surveillance of presumed low risk BD-IPMNs (those without either worrisome features (WF) or high risk stigmata (HRS)) is controversial, and needs to balance the real risk of malignancy or developing malignancy and IPMN-related mortality, with the patient's life expectancy, quality of life expectations, and mortality from non-pancreatic-related causes...
July 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28724304/synchronous-intraductal-papillary-mucinous-neoplasm-and-a-pancreatic-neuroendocrine-tumor-more-than-a-coincidence
#11
Juliana M Costa, Sofia Carvalho, João B Soares
Although the association between intraductal papillary mucinous neoplasm of the pancreas (IPMN) and pancreatic neuroendocrine tumor (PNET) has been increasingly reported, whether this association is real or coincidence remains unclear. We report a case of synchronous IPMN and a PNET which were diagnosed preoperatively and discuss the tumorigenesis, clinicopathological features and management of these rare tumors based on the published literature. A 56-year-old male was incidentally diagnosed with a 14 mm branch duct IPMN and a 3...
July 14, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28700444/multi-institutional-validation-study-of-pancreatic-cyst-fluid-protein-analysis-for-prediction-of-high-risk-intraductal-papillary-mucinous-neoplasms-of-the-pancreas
#12
Mohammad A Al Efishat, Marc F Attiyeh, Anne A Eaton, Mithat Gönen, Denise Prosser, Anna E Lokshin, Carlos Fernández-Del Castillo, Keith D Lillemoe, Cristina R Ferrone, Ilaria Pergolini, Mari Mino-Kenudson, Neda Rezaee, Marco Dal Molin, Matthew J Weiss, John L Cameron, Ralph H Hruban, Michael I D'Angelica, T Peter Kingham, Ronald P DeMatteo, William R Jarnagin, Christopher L Wolfgang, Peter J Allen
OBJECTIVE: Preliminary work by our group suggested that proteins within the pancreatic cyst fluid (CF) may discriminate degree of IPMN dysplasia. We sought to externally validate these markers and determine whether their inclusion in a preoperative clinical nomogram could increase diagnostic accuracy. SUMMARY BACKGROUND DATA: IPMN is the most common radiographically identifiable precursor to pancreatic cancer; however, the timing and frequency of its malignant progression are unknown, and there are currently no reliable preoperative tests that can determine the grade of dysplasia in IPMN...
July 11, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28697137/clinical-profile-of-pancreatic-cystic-lesions-in-von-hippel-lindau-disease-a-series-of-48-patients-seen-at-a-tertiary-institution
#13
Ayush Sharma, Saurabh Mukewar, Santhi Swaroop Vege
OBJECTIVES: Little is known about the association between pancreatic cystic lesions (PCLs) with von Hippel-Lindau disease (VHLD). In this study, we describe the clinical presentation, type of PCLs, and risk for malignancy in PCLs in VHLD. METHODS: Patients given a diagnosis of both VHLD and PCLs were identified from electronic medical records at Mayo Clinic, Rochester, MN, from January 1, 2000, to January 1, 2016. Various demographic, clinical, and radiologic variables were recorded...
August 2017: Pancreas
https://www.readbyqxmd.com/read/28697136/circulating-epithelial-cells-in-intraductal-papillary-mucinous-neoplasms-and-cystic-pancreatic-lesions
#14
Katherine E Poruk, Vicente Valero, Jin He, Nita Ahuja, John L Cameron, Matthew J Weiss, Anne Marie Lennon, Michael Goggins, Laura D Wood, Christopher L Wolfgang
OBJECTIVES: Circulating epithelial cells (CECs) are identified in the blood of patients with intraductal papillary mucinous neoplasms (IPMNs) despite the absence of malignancy. We assessed the blood of patients undergoing resection for IPMN or other benign pancreatic lesions for CECs. METHODS: Peripheral blood was collected from 26 patients prior to pancreatic resection and filtered by the ISET (Isolation by Size of Epithelial Tumor Cells) method. Circulating epithelial cells were identified with antibodies to cytokeratin and Pdx1 (pancreas and duodenal homeobox protein 1), a pancreas marker...
August 2017: Pancreas
https://www.readbyqxmd.com/read/28693147/pancreatic-intraductal-tubulopapillary-neoplasm-with-associated-invasive-cancer-successfully-treated-by-total-pancreatectomy-a-case-report
#15
Yuji Fujimoto, Yoshito Tomimaru, Hiromi Tamura, Kozo Noguchi, Hirotsugu Nagase, Atsushi Hamabe, Masashi Hirota, Kazuteru Oshima, Tsukasa Tanida, Tomono Kawase, Shunji Morita, Hiroshi Imamura, Takashi Iwazawa, Kenzo Akagi, Masashi Yamamoto, Tsutomu Nishida, Shiro Adachi, Keizo Dono
A 74-year-old male was admitted to Departments of Surgery, Toyonaka Municipal Hospital (Osaka, Japan) for treatment of a pancreatic tumor. Contrast enhanced computed tomography (CT) revealed a mass with small cystic lesions in the pancreatic head and body. Fluorodeoxyglucose-positron emission tomography/CT revealed an abnormal uptake of fluorodeoxyglucose, corresponding to the mass lesions. Upper gastrointestinal endoscopy revealed rough mucosa near the opening of the accessory pancreatic duct, and the mucosa biopsy exhibited adenocarcinoma with no mucin observed...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28687431/resectable-invasive-ipmn-versus-sporadic-pancreatic-adenocarcinoma-of-the-head-of-the-pancreas-should-these-two-different-diseases-receive-the-same-treatment-a-matched-comparison-study-of-the-french-surgical-association-afc
#16
P Duconseil, J Périnel, A Autret, M Adham, A Sauvanet, L Chiche, J-Y Mabrut, J-J Tuech, C Mariette, N Régenet, J-M Fabre, P Bachellier, J-R Delpéro, F Paye, O Turrini
PURPOSE: To compare survival and impact of adjuvant chemotherapy in patients who underwent pancreaticoduodenectomy (PD) for invasive intraductal papillary mucinous neoplasm (IIPMN) and sporadic pancreatic ductal adenocarcinoma (PDAC). METHODS: From 2005 to 2012, 240 patients underwent pancreatectomy for IIPMN and 1327 for PDAC. Exclusion criteria included neoadjuvant treatment, pancreatic resection other than PD, vascular resection, carcinoma in situ, or <11 examined lymph nodes...
June 29, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28685935/gastric-gland-mucin-specific-o-glycan-expression-decreases-with-tumor-progression-from-precursor-lesions-to-pancreatic-cancer
#17
Ayumi Ohya, Kazuhiro Yamanoi, Hisashi Shimojo, Chifumi Fujii, Jun Nakayama
Pancreatic cancer is lethal, as it is often detected late. Thus novel biomarkers of precursor lesions are needed to devise timely therapies. Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) are major precursors of pancreatic cancer. In normal gastric mucosa, gastric gland mucin-specific O-glycans are unique in having α1,4-linked N-acetylglucosamine (αGlcNAc) residues attached to MUC6. Recently we reported that αGlcNAc functions as a tumor suppressor for differentiated-type gastric adenocarcinoma (Karasawa et al...
July 7, 2017: Cancer Science
https://www.readbyqxmd.com/read/28682431/uptodate-in-the-assessment-and-management-of-intraductal-papillary-mucinous-neoplasms-of-the-pancreas
#18
D Pagliari, A Saviano, M L Serricchio, A A Dal Lago, M G Brizi, F Lanza, R Manfredi, A Gasbarrini, F Attili
Intraductal Papillary Mucinous Neoplasms (IPMNs) are the most common cystic tumors of the pancreas and are considered premalignant lesions. IPMNs are characterized by the papillary growth of the ductal epithelium with rich mucin production, which is responsible for cystic segmental or diffuse dilatation of the main pancreatic duct (MPD) and/or its branches. According to the different involvement of pancreatic duct system, IPMNs are divided into main duct type (MD-IPMN), branch duct type (BD-IPMN), and mixed type (MT-IPMN)...
June 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28667432/evaluation-of-the-international-consensus-guidelines-for-the-surgical-resection-of-intraductal-papillary-mucinous-neoplasms
#19
Mariko Tsukagoshi, Kenichiro Araki, Fumiyoshi Saito, Norio Kubo, Akira Watanabe, Takamichi Igarashi, Norihiro Ishii, Takahiro Yamanaka, Ken Shirabe, Hiroyuki Kuwano
BACKGROUND: International consensus guidelines for intraductal papillary mucinous neoplasms (IPMNs) were revised in 2012. AIMS: We aimed to evaluate the clinical utility of each predictor in the 2006 and 2012 guidelines and validate the diagnostic value and surgical indications. METHODS: Forty-two patients with surgically resected IPMNs were included. Each predictor was applied to evaluate its diagnostic value. RESULTS: The 2012 guidelines had greater accuracy for invasive carcinoma than the 2006 guidelines (64...
June 30, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28633941/pancreatic-cyst-fluid-vascular-endothelial-growth-factor-a-and-carcinoembryonic-antigen-a-highly-accurate-test-for-the-diagnosis-of-serous-cystic-neoplasm
#20
Rosalie A Carr, Michele T Yip-Schneider, Scott Dolejs, Bradley A Hancock, Huangbing Wu, Milan Radovich, C Max Schmidt
BACKGROUND: Accurate differentiation of pancreatic cystic lesions is important for pancreatic cancer early detection and prevention as well as avoidance of unnecessary surgical intervention. Serous cystic neoplasms (SCN) have no malignant potential, but may mimic premalignant mucinous cystic lesions: mucinous cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN). We recently identified vascular endothelial growth factor (VEGF)-A as a novel pancreatic fluid biomarker for SCN...
May 18, 2017: Journal of the American College of Surgeons
keyword
keyword
17585
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"